ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of ...

Vir Biotechnology has dosed the first patient in one of three expansion cohorts in its ongoing Phase I clinical trial of ...

Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that ...

ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.

“After treatment with enzalutamide, PSA levels decline due to potent androgen receptor blockade and cell death,” Armstrong ...

The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...

Drugs used for prostate cancer may not increase bleeding or clotting risks when used with blood thinners, thus providing ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane ...

ACE-106 demonstrated notable anti-tumour activity across different tumour types.